GW posts gain ahead of Epidiolex panel

GW Pharmaceuticals plc (NASDAQ:GWPH) climbed $13.55 (11%) to $134.13 on Tuesday after FDA released briefing documents ahead of an advisory committee's planned April 19 meeting concerning an NDA for Epidiolex cannabidiol to treat Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

FDA's Peripheral and Central Nervous System Drugs Advisory Committee will vote on whether Epidiolex's benefit-risk profile is favorable in patients ages two and older based on existing Phase III data in both seizure disorders...